Keep Current with the Latest in Cell Biology Research
Block title
Spontaneous Upregulation of Stemness and 3D Spheroid Formation of Single Cancer Cells Induced by Scaffold-Free Polypeptide Polyelectrolyte Multilayer Coating
[Biomaterials] Scientists presented a polyelectrolyte multilayer-based surface coating designed to promote rapid spheroid formation from individual cancer cells.
Aging-Associated Differences in Mammary Tumor-Initiating Populations and Immune Evasion Pathways in Breast Cancer
[Proceedings of The National Academy of Sciences of The United States of America] While scientists showed a strong molecular resemblance between Aging-luminal progenitors (ALPs) in aged normal tissue and ALP-like cancer cells, proving that ALPs are the normal cell-of-origin of ALP-like tumors remains to be established by future lineage-tracing experiments.
Targeting Cancer Stem Cells Predicts Response and Reverses Chemoresistance in Ascites-Derived Ovarian Cancer Organoids
[BMC Medicine] The expression of CSC markers CD44 and ALDH1A1 under treatment conditions was analyzed using immunohistochemistry and flow cytometry.
Targeting Melanoma-Associated Fibroblasts to Overcome Cancer Stem Cell-Driven Drug Resistance
[Journal of the American College of Surgeons] Activating Notch1 signaling in melanoma-associated fibroblasts overcomes BRAF inhibitor resistance by disrupting cancer stem cell niches.
Human Papillomavirus16 E7 Enhances Cell Stemness by Regulating the APC2/SPIN4/β-catenin Axis in Cervical Cancer
[Oncogenesis] Researchers revealed a novel HPV16 E7-APC2-SPIN4 axis as a key driver of cervical cancer. In this pathway, APC2 unexpectedly functions as an oncogene by activating the Wnt/β-catenin signaling to promote tumorigenesis and CSC properties.
The Activation of miR-203a by SFRP4 Micropeptides Targets Epithelial-Mesenchymal Transition and Autophagy in Ovarian Cancer Stem Cells
[Molecular Carcinogenesis] Based on preliminary investigation, which showed that miR-203a was downregulated in ovarian CSCs and was subsequently activated by treatment with SFRP4 micropeptides, scientists investigated whether miR-203a plays any part in SFRP4 micropeptide-mediated ovarian CSC inhibition in PA-1 and SKOV-3 cell lines.
Analysis of Cancer Stem Cell Mechanism and Immune Profiling in Breast Cancer of Unknown Primary
[Clinical and Experimental Medicine] Samples of thirteen breast cancers of unknown primarys and five known metastatic breast cancers were subjected to gene expression analysis. The identified CSC phenotype induced by the overexpression of T cell leukemia/lymphoma-1 A was validated via cytological experiments.
Oncofetal Chondroitin Sulfate Positive Circulating Tumor Cells As Prognostic Biomarkers in Early-Stage Melanoma
[Scientific Reports] Investigators used an enrichment method based on recombinant Plasmodium falciparum VAR2CSA protein to enable the capture of rare circulating tumor cells from a single blood draw in early-stage melanoma patients.
CD133+ Lung Cancer Stem-Like Cells Resist Plasma-Activated Medium through PRDX5-Mediated Antioxidant Defense
[Anticancer Research] Researchers elucidated the molecular mechanisms underlying CSC resistance to PAM-induced oxidative stress in non-small cell lung cancer.
Emerging Roles of Pseudogene-Derived lncRNAs in Cancer Stem Cells: Non-Coding Clues and Therapeutic Targets in Cancer Medicine
[Genes & Diseases] The authors comprehensively address the recent findings of previous studies on the dysregulated roles of pseudogene-derived lncRNAs in directing and generating CSCs in various cancers.
Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib
[Certara, Inc.] Certara, Inc. announced its Simcyp® Simulator enabled physiologically-based pharmacokinetic modeling predictions accepted by the US FDA in lieu of clinical studies to support the new drug application for asciminib.
Blackstone Life Sciences Announces a Co-Funding Agreement for Acute Myeloid Leukemia
[Blackstone Life Sciences] Blackstone Life Sciences announced a research and development funding agreement to advance the clinical development of bleximenib (JNJ-75276617), an investigational oral menin inhibitor, for AML.

Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
